MolecularMD Announces Next Generation Sequencing Presentation at Upcoming American Society of Hematology Annual Meeting

PORTLAND, OR--(Marketwire - Dec 6, 2012) - MolecularMD Corp. announced today that it will present data at the annual meeting of the American Society of Hematology conference, pertaining to the development of a Next Generation Sequencing (NGS) test for detection of resistant mutations in patients diagnosed with Chronic Myelogenous Leukemia (CML). 

The poster presentation demonstrates MolecularMD's leadership as a provider of innovative and reliable molecular diagnostic solutions for CML patients treated with tyrosine kinase inhibitors (TKIs).

MolecularMD provides molecular diagnostic testing to support several phase II and phase III trials of ABL TKIs, including the investigational BCR-ABL inhibitor ponatinib. The U.S. Food and Drug Administration (FDA) recently accepted the ponatinib New Drug Application (NDA) for filing and accelerated review. 

MolecularMD scientists will present a poster describing development and clinical validation of a BCR-ABL1 Next-Generation Sequencing Assay. 

ASH Presentation Details
Title: Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance
Poster Session: 611. Leukemias - Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster II
Date & Time: Sunday, December 9, 2012, 6:00 p.m. - 8:00 p.m.
Abstract No.: 2549
Presenter: Jin Li, Ph.D. (MolecularMD Corp.)
Location: Hall B1-B2

About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD incorporates gold-standard and innovative technologies in providing its partners with the highest quality results. Assays are designed to meet clinical trial needs, and MolecularMD has appropriate systems and standards in place to enable development of companion diagnostic tests in conjunction with partners' novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Brian Druker, director of the Knight Cancer Center at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation.